dc.contributorPrada Rico, Mayerly
dc.contributorBermúdez-Hernández, Pablo Andrés
dc.creatorPiñeros Chávez, Laura
dc.date.accessioned2020-08-20T16:10:43Z
dc.date.accessioned2022-09-22T13:58:32Z
dc.date.available2020-08-20T16:10:43Z
dc.date.available2022-09-22T13:58:32Z
dc.date.created2020-08-20T16:10:43Z
dc.identifierhttps://repository.urosario.edu.co/handle/10336/28185
dc.identifierhttps://doi.org/10.48713/10336_28185
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3434599
dc.description.abstractBackground: Hypomagnesemia is a frequent condition in renal transplant patients. The use of calcineurin inhibitors (CNIs) is related with this disorder. It is important to evaluate factors that are associated with hypomagnesemia given the multiple complications linked to it. Others studies have described other associations with this outcome, as: the use of proton pump inhibitor (PPI), low glomerular filtration rates and the early stage after renal transplant (2). Aim: To establish the frequency and factors related to the development of hypomagnesemia in the pediatric kidney post transplant period. Methods: Cross-section study which evaluated factors associated to hypomagnesemia in the post-transplant period in renal transplant pediatric patient at Fundacion Cardioinfantil. Bivariate analysis of means comparison was carried out after checking normality tests. For categorical variables, adjusted ORs were obtained, taking post-transplant hypomagnesemia as an independent variable. Results: A total of 99 patients were evaluated. Prevalence of hypomagnesemia was 42,4% (42/99) in the post-transplant period. In the first month after kidney transplant 71,4% patient presented hypomagnesemia. There was association between hypomagnesemia and cadaveric donor type [92,9% (39); p=0,049; OR 3,46; IC 0,91-13,18]. No association was found between use of calcineurin inhibitors, nutritional status or electrolyte abnormalities. Discussion: Hypomagnesemia is a frequent complication found in renal transplant patients. Knowing the factors associated with hipomagnesemia is important to generate intervention. Use of calcineurin inhibitors, treatment with PPI and the first month after transplantation, have been related to the development of hypomagnesemia (2-4). In this study it was found an association between hipomagnesemia and cadaveric donor type. Conclusions: Hypomagnesemia in the early stages after renal transplantation is frequent complication. It can persist for long time periods and it is more common in the first month post-transplantation. In our study, there was a prevalence of 42,4%, cadaveric donor was the only factor associated with this outcome.
dc.languagespa
dc.publisherUniversidad del Rosario
dc.publisherEspecialización en Pediatría
dc.publisherFacultad de medicina
dc.rightshttp://creativecommons.org/licenses/by/2.5/co/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto Completo)
dc.rightsEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.
dc.rightsFundación Cardioinfantil
dc.rightsAtribución 2.5 Colombia
dc.sourceCheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, Srivali N, Edmonds PJ, Ungprasert P, et al. Proton pump inhibitors linked to hypomagnesemia: A systematic review and meta-analysis of observational studies. Ren Fail. 2015;37(7):1237–41.
dc.sourceUslu Gökceoǧlu A, Comak E, Dogan CS, Koyun M, Akbas H, Akman S. Magnesium excretion and hypomagnesemia in pediatric renal transplant recipients. Ren Fail. 2014;36(7):1056–9.
dc.sourceTrompeter R, Filler G, Webb NJA, Watson AR, Milford D V., Tyden G, et al. Randomized trial of tracolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol. 2002;17(3):141–9.
dc.sourceDouwes RM, Gomes-Neto AW, Schutten JC, van den Berg E, de Borst MH, Berger SP, et al. Proton-Pump Inhibitors and Hypomagnesaemia in Kidney Transplant Recipients. J Clin Med. 2019;8(12):2162.
dc.sourceFiller G. Calcineurin inhibitors in pediatric renal transplant recipients. Paediatr Drugs. 2007;9(3):165–74.
dc.sourceVan Laecke S, Van Biesen W. Hypomagnesaemia in kidney transplantation. Transplant Rev [Internet]. 2015;29(3):154–60. Available from: http://dx.doi.org/10.1016/j.trre.2015.05.002
dc.sourceNavaneethan SD, Sankarasubbaiyan S, Gross MD, Jeevanantham V, Monk RD. Tacrolimus-Associated Hypomagnesemia in Renal Transplant Recipients. Transplant Proc. 2006;38(5):1320–2
dc.sourceRodrigues N, Santana A, Guerra J, Neves M, Nascimento C, Gonçalves J, et al. Serum Magnesium and Related Factors in Long-Term Renal Transplant Recipients: An Observational Study. Transplant Proc. 2017;49(4):799–802.
dc.sourceQuamme, GA; Dirks J. The Physiology of Renal Magnesium Handling. Ren Physiol. 1986;9:257–69.
dc.sourceHouillier P. Mechanisms and regulation of renal magnesium transport. Annu Rev Physiol. 2014;76:411–30.
dc.sourceBlaine J, Chonchol M, Levi M. Renal control of calcium, phosphate, and magnesium homeostasis. Clin J Am Soc Nephrol. 2015;10(7):1257–72.
dc.sourceCheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, Srivali N, Edmonds PJ, Ungprasert P, et al. Proton pump inhibitors linked to hypomagnesemia: A systematic review and meta-analysis of observational studies. Ren Fail. 2015;37(7):1237–41.
dc.sourcePark CH, Kim EH, Roh YH, Kim HY, Lee SK. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: A systematic review and meta-analysis. PLoS One. 2014;9(11).
dc.sourceGuyton AC HH. Tratado de fisiología médica. 11a ed. Bonet Serra B, editor. Barcelona: Elsevier; 2006.
dc.sourceRomani AMP. Cellular magnesium homeostasis. Arch Biochem Biophys. 2011;512(1):1–23.
dc.sourceTrompeter R, Filler G, Webb NJ a, Watson AR, Milford D V, Tyden G, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol. 2002;17(3):141–9.
dc.sourceCastiglioni S, Cazzaniga A, Albisetti W, Maier J. Magnesium and Osteoporosis: Current State of Knowledge and Future Research Directions. Nutrients. 2013;5(8):3022–33.
dc.sourceVan Laecke S, Vermeiren P, Nagler E V., Caluwe R, De Wilde M, Van der Vennet M, et al. Magnesium and infection risk after kidney transplantation: An observational cohort study. J Infect. 2016;73(1):8–17.
dc.sourceMiles CD, Westphal SG. Electrolyte disorders in kidney transplantation. Clin J Am Soc Nephrol. 2020;15(3):412–4.
dc.sourceDe Waele L, Van Gaal PJ, Abramowicz D. Electrolytes disturbances after kidney transplantation. Acta Clin Belgica Int J Clin Lab Med. 2019;74(1):48–52.
dc.sourceVan Laecke S. Hypomagnesemia and hypermagnesemia. Acta Clin Belgica Int J Clin Lab Med [Internet]. 2019;74(1):41–7. Available from: https://doi.org/10.1080/17843286.2018.1516173
dc.sourceOsorio JM, Bravo J, Pérez A, Ferreyra C, Osuna A. Magnesemia in renal transplant recipients: Relation with immunosuppression and posttransplant diabetes. Transplant Proc [Internet]. 2010;42(8):2910–3. Available from: http://dx.doi.org/10.1016/j.transproceed.2010.08.016
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectHipomagnesemia
dc.subjectTrasplante renal
dc.subjectEnfermedad renal terminal
dc.subjectInhibidor de calcineurina
dc.titleFactores relacionados con el desarrollo de Hipomagnesemia en el postrasplante renal pediátrico en la Fundación Cardio-Infantil de Bogotá durante el periodo 2006-2018
dc.typemasterThesis


Este ítem pertenece a la siguiente institución